AstraZeneca PLC

Pharmaceutical industry

AstraZeneca's Tagrisso Receives Positive Opinion for Marketing Authorization in the European Union

AstraZeneca's Tagrisso, a third-generation, irreversible EGFR-TKI, has received a positive opinion for marketing authorization in the European Union for the adjuvant treatment of adult patients with early-stage epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after complete tumour resection with curative intent. This decision is based

Pharmaceutical industry

Immunotherapy-Related Pneumonitis in Cancer Patients Continues to Pose Challenges

Researchers have reported two cases of cancer patients experiencing pneumonitis, a severe and potentially life-threatening side effect, while undergoing immunotherapy with anti-programmed cell death 1 (PD-1) inhibitors. Despite the discontinuation of immunotherapy, both patients remained in complete remission for over a year. This study highlights the ongoing challenges and risks